Jul 2026 (Q1 FY27) — Sep 10, 2026
Champions Oncology Q1 FY27 — Strong Revenue Growth and Margin Expansion
Read the full callChampions Oncology (CSBR) earnings
- Jul 2026
- Jul 2026 (Q1 FY27)
- Apr 2026
Champions Oncology earnings: last reported Thu, 10 Sep 2026, for the quarter ended Jul 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 15.2 | +8.8% YoY | Quarterly, as filed | Quarter to Jul 2026 | Revenue from operations as filed. |
| Operating margin | -2.7 | +1.1 pts YoY | Operating profit / revenue | Quarter to Jul 2026 | For the quarter; a change is in percentage points. |
| Net profit | -0.43 | Quarterly, as filed | Quarter to Jul 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$4.79 −0.42% · −$0.02
Performance −27.5% 1Y
1Y: $6.61 on 14 Oct 2025 → $4.79. High $7.8 (15 Dec 2025), low $4.77 (15 Sept 2026).
- Previous close
- $4.81
- 52-week range
- $4.77 – $7.8
- One year
- −27.20%
Overview
- Symbol
- CSBR
- Exchange
- US
- Currency
- USD
Call summaries
Apr 2026 (Q4 FY26) — Jul 27, 2026
Champions Oncology Q4 FY26 — Record Revenue and Positive Adjusted EBITDA
Read the full callEvery analysed call
Champions Oncology earnings calls (CSBR)
Financials
What the filings say
Net profit, year on year: +9% (quarter to jul 2026 against jul 2025).
| Line item | Oct 2024 | Jan 2025 | Apr 2025 | Jul 2025 | Oct 2025 | Jan 2026 | Apr 2026 | Jul 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 13 | 17 | 12 | 14 | 15 | 17 | 14 | 15 |
| Operating profit | 1 | 4 | -2 | -1 | 0 | -0 | -1 | -0 |
| Operating margin | 5.4% | 26.4% | −16.2% | −3.8% | 1.2% | −1.7% | −3.8% | −2.7% |
| Profit before tax | 1 | 5 | -2 | -0 | 0 | -0 | -0 | -0 |
| Tax rate | 1.5% | 0.5% | 6.6% | −3.1% | 7.1% | −17.7% | −34.8% | −2.6% |
| Net profit | 1 | 4 | -2 | -0 | 0 | -0 | — | -0 |
| EPS ($ per share) | 0.05 | 0.33 | — | -0.03 | 0.02 | -0.02 | — | -0.03 |
| Line item | Apr 2019 | Apr 2020 | Apr 2021 | Apr 2022 | Apr 2023 | Apr 2024 | Apr 2025 | Apr 2026 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -71 | -73 | -73 | -72 | -77 | -85 | -80 | -81 |
| Total liabilities | 9 | 16 | 20 | 26 | 30 | 28 | 29 | 23 |
| Fixed assets | 3 | 4 | 6 | 7 | 7 | 6 | 4 | 4 |
| Total assets | 11 | 21 | 28 | 35 | 34 | 26 | 32 | 27 |
| Line item | Apr 2019 | Apr 2020 | Apr 2021 | Apr 2022 | Apr 2023 | Apr 2024 | Apr 2025 | Apr 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 2 | 3 | -2 | 6 | 4 | -6 | 7 | -4 |
| Cash from investing | -1 | -2 | -3 | -2 | -3 | -1 | -0 | -1 |
| Cash from financing | 1 | 4 | 1 | 0 | 0 | -1 | 0 | 0 |
| Net cash flow | 2 | 5 | -4 | 4 | 1 | -7 | 7 | -5 |
| Capital expenditure | -1 | -2 | -3 | -2 | -3 | -1 | -0 | -1 |
| Free cash flow | 1 | 1 | -5 | 4 | 1 | -7 | 7 | -5 |
Insider filings
1 filing, all on Oct 30, 2025.
Open market
decisions to buy or sellNobody bought or sold CSBR on the open market in this window. The filing below is 1 option exercise.
Compensation
not trading decisions- 1
- Option exercise — converted options into shares
Latest filings (4)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Oct 30, 2025 | ACKERMAN JOEL Director | Option exercise | 94,405 | $198.3K |
| Mar 25, 2025 | Breitfeld Philip P. Director | Other | 4,150 | $0 |
| Oct 31, 2024 | ACKERMAN JOEL Director | Option exercise | 88,470 | $185.8K |
| Oct 31, 2024 | ACKERMAN JOEL Director | Option exercise | 16,667 | $90.5K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for CHAMPIONS ONCOLOGY, INC.
Free account. Everything above stays public.
Write why you follow CHAMPIONS ONCOLOGY, INC. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading